FORA Capital’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

FORA Capital’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,772	Closed	-$64K	–	1251
2020 Q4	$64K	Buy	+2,772	New	+$35.1K	0.01%	740

FORA Capital's PRVL Position: Q1 2021 in Review

FORA Capital sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 2,772 shares — an estimated $64K sold.

FORA Capital first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $64K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

FORA Capital reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
FORA Capital sold 2,772 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $64K.
FORA Capital first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
FORA Capital's Prevail Therapeutics Inc. Common Stock position peaked at $64K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on FORA Capital's 13F filing for Q1 2021, filed 17 May 2021.